Breakout Stocks of Week 38
NASDAQ was down last week (week 37) by -1.61% ending at 15,115.49 points after falling -248.03 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Experian Plc XLON:EXPN. This stock has had a buy signal since Jun 15, 2021 when the price was £2,745.00 and is so far up 21.38% to £3,332.00. Some other companies are on our watchlist to, among these are Hypoport SE GER:HYQ Daré Bioscience, Inc. NASDAQ:DARE Verve Therapeutics, Inc. NASDAQ:VERV and Howden Joinery Group Plc XLON:HWDN which all got a breakout pattern emerging.
| Date | Company | Price | Week 38 |
|---|---|---|---|
| Experian Plc | £3,332.00 | £3,312.00 | -0.600% |
| Hypoport Se | 600.00€ | 595.00€ | -0.83% |
| Daré Bioscience, Inc. | $1.65 | $1.77 | 7.27% |
| Verve Therapeutics, Inc. | $73.99 | $59.88 | -19.07% |
| Howden Joinery Group Plc | £964.80 | £960.80 | -0.415% |
The Experian Plc stock price gained 2.46% on the last trading day (Friday, 10th Sep 2021), rising from £3,252.00 to £3,332.00. During the last trading day the stock fluctuated 2.39% from a day low at £3,264.00 to a day high of £3,342.00. The price has risen in 6 of the last 10 days and is up by 4.65% over the past 2 weeks. Volume fell on the last day by -504 thousand shares and in total, 1 million shares were bought and sold for approximately £4.13 billion. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Experian Plc holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Experian Plc:
Experian plc, together with its subsidiaries, operates as a technology company. The company operates through two segments, Business-to-Business and Consumer Services. It provides data services to identify and understand the customers, as well as to manage the risks related with lending. The company also offers analytical and decision tools that enhance businesses to manage their customers, minimize the risk of fraud, comply with legal requirements, and automate decisions and processes. In addition, it provides financial education, free access to Experian credit reports and scores, online educational tools, and applications to manage their financial position, access credit offers, and protect themselves from identity fraud. The company serves customers in financial service, direct-to-consumer, health, retail, automotive, software and professional services, telecommunications and utility, insurance, media and technology, government and public, and other sectors. It operates in North America, Latin America, the United Kingdom, Ireland, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Experian Group Limited and changed its name to Experian plc in July 2008. Experian plc was founded in 1826 and is headquartered in Dublin, Ireland.
The Hypoport SE stock price gained 0.0834% on the last trading day (Friday, 10th Sep 2021), rising from 599.50€ to 600.00€. During the last trading day the stock fluctuated 2.43% from a day low at 597.50€ to a day high of 612.00€. The price has risen in 6 of the last 10 days and is up by 2.21% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 651 more shares were traded than the day before. In total, 6 thousand shares were bought and sold for approximately 3.79€ million.
Hypoport SE holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Hypoport SE:
Hypoport SE operates as a technology-based financial service provider in Germany. The company operates through four segments: Credit Platform, Private Clients, Real Estate Platform, and Insurance Platform. It offers EUROPACE marketplace for independent distributors to process their financing transactions with the product suppliers they represent. The company also provides mortgage finance, personal loans, insurance, and current and deposit accounts through distribution channels, including online and branch-based sales. In addition, it offers advice and customized solutions in the areas of financial management, portfolio management, and insurance for business customers; PRoMMiSe, a software that helps banks with the analysis and reporting of securitized or collateralized loan portfolios; Software as a Service for banks and housing companies; and property valuation services, as well as supports issuers with the provision of information technology and a range of services. Further, it develops and operates software solutions for the sale and management of insurance products; operates SMART INSUR, a web-based B2B platform for advice, comparison of tariffs, and the administration of insurance policies; and provides support services to small and medium-sized financial product distributors in relation to the brokerage of insurance policies. The company was founded in 1954 and is headquartered in Lübeck, Germany.
The Daré Bioscience, Inc. stock price fell by -3.51% on the last day (Friday, 10th Sep 2021) from $1.71 to $1.65. During the last trading day the stock fluctuated 4.24% from a day low at $1.65 to a day high of $1.72. The price has been going up and down for this period, and there has been a -4.62% loss for the last 2 weeks. Volume has increased on the last day by 704 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $3.51 million.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Daré Bioscience, Inc. stock to perform well in the short-term.
About Daré Bioscience, Inc.:
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
The Verve Therapeutics, Inc. stock price gained 1.00% on the last trading day (Friday, 10th Sep 2021), rising from $73.26 to $73.99. During the last trading day the stock fluctuated 3.03% from a day low at $73.33 to a day high of $75.55. The price has risen in 6 of the last 10 days and is up by 12.43% over the past 2 weeks. Volume fell on the last day by -77 thousand shares and in total, 295 thousand shares were bought and sold for approximately $21.86 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
On Apr 08, 2024, it was reported that H.C. Wainwright gave VERV a "Buy" grade with a "initialise" action.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Verve Therapeutics, Inc. stock to perform well in the short-term.
About Verve Therapeutics, Inc.:
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
The Howden Joinery Group Plc stock price gained 1.66% on the last trading day (Friday, 10th Sep 2021), rising from £949.00 to £964.80. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 1.85% from a day low at £949.80 to a day high of £967.40. The price has risen in 7 of the last 10 days and is up by 1.84% over the past 2 weeks. Volume fell on the last day by -1 million shares and in total, 640 thousand shares were bought and sold for approximately £617.77 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Howden Joinery Group Plc stock to perform well in the short-term.
About Howden Joinery Group Plc:
Howden Joinery Group Plc, a trade kitchen supplier, provides various products across kitchens, joinery, and hardware in the United Kingdom, France, and Belgium. It offers kitchen cabinets, surfaces, fittings, storages, fitted kitchens, kitchen doors, sinks, and taps, as well as appliances; joinery products, such as sliding wardrobe doors, door fittings, stairs and parts, floors, skirting boards, mouldings, doors, and architrave products; and appliances, such as cooking, refrigerator, dishwasher, and laundry products, as well as coffee machines. The company was incorporated in 1987 and is based in London, the United Kingdom.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
